II FROM FUNDAMENTALS TO CLINICAL APPLICATIONS

In vitro effects of polyvalent immunoglobulin for intravenous use

I N van Schaik, M Vermeulen, A Brand

High dose intravenous immunoglobulin (IVIg) therapy is used in the treatment of a wide range of auto-immune or presumed immune-mediated neurological disorders. A beneficial effect of IVIg has been reported in Guillain-Barré syndrome,¹ chronic inflammatory demyelinating polyneuropathy,²⁻⁶ myasthenia gravis,^{7,8} multiple sclerosis,⁹ multifocal motor neuropathy,¹⁰⁻¹² intractable childhood epilepsy,¹³ and dermato- and polymyositis.^{14,15}

The mechanisms of response to IVIg treatment in these disorders is not fully understood. Firstly, adequate models to study the effects of IVIg are lacking. Secondly, treatment with IVIg has probably multiple effects on induction and amplification, as well as the effector phase of the immune response.

Effects of IVIg on the effector phase of the immune response

Most studies on IVIg have dealt with the effector phase of the immune response. It has been demonstrated that IVIg has the following effects *in vivo*: inhibition of autoantibody production,¹⁶ neutralisation of circulating pathogenic antibodies,¹⁷⁻²¹ and decrease of antibody dependent cellular cytotoxicity (ADCC) by Fc receptor blockade.²² *In vitro* it was shown that IVIg inhibits pokeweed mitogen stimulated antibody production,²³⁻²⁶ contains anti-idiotypic antibodies against multiple auto-antibodies,^{18-21,27-29} suppresses ADCC,³⁰⁻³² decreases natural killer cell function,³³ and interferes with complement-activation.^{34,35} These mechanisms are dependent on the presence of the intact IgG molecule, which has a half-life of approximately three weeks *in vivo*.³⁶ However, the observed long term effect of IVIg treatment, in some diseases for up to three months, is not fully explained by the modes of action already mentioned. IVIg may therefore modulate auto-immunity at other levels of the immune response.

Effects of IVIg on the induction and amplification phase of the immune response**ANTIPROLIFERATIVE EFFECTS**

The effects of IVIg on the induction and amplification of the immune response in which the CD4⁺ helper T-cell interacts with

antigen presenting cells (in a way that costimulatory signals are activated) has not yet been explored. Interactions of IVIg with T-cells have been scarcely investigated.³⁷ An enhancement of CD8 positive suppressor T-cell function *in vivo* has been reported.³⁸⁻⁴⁰ Furthermore, IVIg appears to interfere with the cytokine network. *In vitro* administration of IVIg results in induction of the interleukin-1 receptor antagonist and downregulation of the production of Il-1 and tumour necrosis factor- α . Moreover, antibodies against Il-1 α have been demonstrated in IVIg.⁴¹⁻⁴³

We recently showed inhibitory effects of IVIg on antigen-specific and non-specific stimulated lymphocytes.⁴⁴ Subsequent experiments showed that IVIg added to cultures of various autonomously growing cell lines (including the haematopoietic cells HL-60, Daudi, Molt-4 and K562, B-cell hybridomas, EBV transformed B-cells and neuroblastoma cell lines of various human and non-human origin) also ceased with proliferation. We demonstrated that IVIg interfered with DNA-synthesis and protein metabolism. ³H-thymidine uptake of activated cells was measured, after incubation with IVIg for various intervals. IVIg interferes with ³H-thymidine uptake, in a dose-dependent fashion, regardless of the stimulus. To confirm these observations, cells cultured with and without IVIg, were pulse-labelled with bromodeoxyuridine (BrdU) and subsequently analysed in an immunofluorescence-assay. The BrdU labelling studies showed that cells were arrested in the G₀-/G₁- and no longer progressed into the S-phase. Similar results were obtained with normal human myoblasts and fibroblasts in culture. Parallel experiments with similar concentrations of human albumin did not show these effects. There was no apparent cytotoxic effect, as removal of IVIg within an interval of several days and reculturing in fresh medium, resulted in normal proliferation of K562, HL-60, EBV transformed B-cells, human myoblast and fibroblast. Further experiments are needed to exclude that a proportion of cells are induced to apoptosis.

GROWTH FACTOR SIGNALLING

A possible explanation for this broad proliferative arrest could be the interference of IVIg with essential growth factors. Il-1 α , Il-2, Il-3

Department of
Immunohaematology,
University Hospital
Leiden, Leiden, The
Netherlands
I N van Schaik
A Brand

Department of
Neurology,
*Academic Medical
Center, Amsterdam,
The Netherlands
M Vermeulen

Correspondence to:
Dr I N van Schaik,
Department of Neurology
H2, Academic Medical
Center, Meibergdreef 9,
1105 AZ Amsterdam, The
Netherlands.

Putative effects of IVIg on induction, amplification and effector phase of the immune response.

Induction and activation phase

Effect on signal transduction
Inhibitory effect on antigen-specific stimulated lymphocytes*
Inhibitory effect on antigen non-specific stimulated lymphocytes (PHA, PWM)*
Enhancement of CD8 positive suppressor T-cell function*
CD4 helper T-cell activation

Amplification phase

Effect on co-stimulatory cells
Effect on accessory cells*
Interference with the cytokine network*
Proliferation and maturation phase
Interference with growth factors (receptors and production)
Interference with DNA synthesis*
Interference with protein metabolism
Interference with antibody production*

Effector phase

Binding to FcγI,II,III receptors*
Neutralisation of circulating pathogenic antibodies*
Anti-idiotypic interactions*
Decrease of ADCC by Fcγ receptor blockade*
Decrease of natural killer cell function*
Interference with complement activation*

* published effects of IVIg, see text.

and supernatant of lymphokine (CD3 and IL-2) activated killer cells were therefore added in increasing doses to lymphocytes in various antigen specific and antigen non-specific stimulated models, as well as to various autonomously growing cell-lines. However, this could not abolish the inhibitory effect of IVIg. These results suggest that these interleukins do not interact with IVIg.

There are many similarities between IVIg and tumour growth factor-β. TGF-β has inhibitory effects on various T-cell and B-cell interactions and activities, on tumour cells and normal cell proliferation.^{45,46} To exclude the possibility that IVIg contains TGF-β activity we added anti-TGF-β neutralising antibody to IVIg. Despite increasing doses of this antibody we found no reduction of the anti-proliferative effect of IVIg.

Fcγ-RECEPTOR SIGNALLING

Another explanation for the anti-proliferative action of IVIg could be the binding to a receptor providing essential cofactors for growth of activated or autonomous proliferating cells. Fcγ-receptors might be the common denominator between the various cell types affected by IVIg. The expression of the distinct Fcγ-receptors was measured in an immunofluorescence assay using monoclonal antibodies against CD64 (FcγRI), CD32 (FcγRII), and CD16 (FcγRIII).⁴⁷ However, most cells are lacking FcγI, II, and III receptor expression. IVIg contains multiple antibodies against polymorphic (HLA class I or II) and non-polymorphic (CD5 receptor) structures.^{48,49} Binding of IVIg to HLA antigens is an unlikely explanation for this effect as some cell lines which were inhibited in a dose-dependent fashion by IVIg, for instance the Daudi cell-line, do not express HLA antigens on their surface.

Conclusion

Our results show that, in addition to the F(ab)₂-mediated anti-idiotypic neutralisation

of autoantibodies, the Fc-mediated immunoregulation of B-cell function and the depression of monocyte effector ADCC-function, IVIg interferes with cell proliferation in vitro and reversibly arrests growth of various cell populations. By which mechanism(s) this inhibitory effect of IVIg on cell proliferation is mediated is currently under study. Besides the interference on the effector phase of the immune response, IVIg profoundly modulates in vitro the induction and probably the amplification phase of the immune response.

- 1 Van der Meché FGA, Schmitz PIM, The Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. *N Engl J Med* 1992;326:1123-9.
- 2 Van Doorn PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. *Arch Neurol* 1991;48:217-20.
- 3 Cornblath DR, Chaudhry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. *Ann Neurol* 1991;30:104-6.
- 4 Vermeulen M, Van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. *J Neurol Sci* 1985;70:317-26.
- 5 Van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. *Neurology* 1990;40:209-12.
- 6 Vermeulen M, Van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. *J Neurol Neurosurg Psychiatry* 1993;56:36-9.
- 7 Arsura E. Experience with intravenous immunoglobulin in myasthenia gravis. *Clin Immunol Immunopathol* 1989;53:S170-9.
- 8 Cook L, Howard JF, Folds JD. Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis. *J Clin Immunol* 1988;8:23-31.
- 9 Schuller E, Govaerts A. First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. *Eur Neurol* 1993;22:205-12.
- 10 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. *Neurology* 1992;42:506-9.
- 11 Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. *Ann Neurol* 1993;33:237-42.
- 12 Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. *Neurology* 1993;43:537-44.
- 13 Illum N, Tandorf K, Heilmann C, et al. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. *Neuropediatrics* 1990;21:87-90.
- 14 Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM. Treatment of dermatomyositis with intravenous gammaglobulin. *Am J Med* 1991;91:169-72.
- 15 Cherin P, Herson S, Wechsler B. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. *Am J Med* 1991;91:162-8.
- 16 Jayne DRW, Davies MJ, Fox CJV, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. *Lancet* 1991;337:1137-9.
- 17 Sultan Y, Kazatchkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous Immunoglobulin in the treatment of spontaneously acquired factor VIII:C inhibitors. *Am J Med* 1991;91:35A-35S-39S.
- 18 Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antidiotypes against anti-VIII:C autoantibodies. *P Natl Acad Sci USA* 1987;84:828-31.
- 19 McGuire W, Yang HH, Bruno E, et al. Treatment of antibody-mediated pure red-cell aplasia with high-dose intravenous gamma globulin. *N Engl J Med* 1987;317:1004-8.
- 20 Brand A, Witvliet M, Claas FHJ, Eernisse JG. Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies. *Brit J Haematol* 1988;70:1-5.
- 21 Lundkvist I, Van Doorn PA, Vermeulen M, Van Lint M, Van Rood JJ, Brand A. Regulation of autoantibodies in inflammatory demyelinating polyneuropathy: spontaneous and therapeutic. *Immunol Rev* 1989;110:105-17.

- 22 Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. *N Engl J Med* 1982;306:1254-8.
- 23 Hashimoto F, Sakiyama Y, Matsumoto S. The suppressive effect of gammaglobulin preparations on in vitro pokeweed mitogen-induced immunoglobulin production. *Clin Exp Immunol* 1986;65:409-15.
- 24 Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. *J Immunol* 1986;136:4407-13.
- 25 Kondo N, Ozawa T, Mushiaki K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. *J Clin Immunol* 1991;11:152-8.
- 26 Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. *Clin Exp Immunol* 1983;53:697-702.
- 27 Rossi F, Kazatchkine MD. Antidiotypes against autoantibodies in pooled normal human polyspecific Ig. *J Immunol* 1989;143:4104-9.
- 28 Lundkvist I, Van Doorn PA, Vermeulen M, Brand A. Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies. *Clin Immunol Immunopathol* 1993;67:192-8.
- 29 Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine MD. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines an idiotype that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). *J Autoimmun* 1990;3:547-57.
- 30 Jungi TW, Santer M, Lerch PG, Barandun S. Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. *Vox Sang* 1986;51:18-26.
- 31 Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. *J Clin Invest* 1980;66:773-81.
- 32 Saleh M, Court W, Huster W, Shaw D, Lobuglio A. Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets. *Brit J Haematol* 1988;68:47-51.
- 33 Engelhard D, Waner JL, Kapoor N, Good RA. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. *J Pediatr* 1986;108:77-81.
- 34 Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. *Clin Immunol Immunopathol* 1992;62:S82-S86.
- 35 Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin; Attenuation of acute, complement-dependent immune damage in a guinea pig model. *J Clin Invest* 1989;84:1974-81.
- 36 Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune diseases. *Clin Exp Immunol* 1991;86:192-8.
- 37 Kawada K, Terasaki PI. Evidence for immunosuppression by high-dose gammaglobulin. *Exp Hematol* 1987;15:133-6.
- 38 Delfraissy JF, Tchernia G, Laurian Y, Wallon C, Galanaud P, Dormont J. Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. *Brit J Haematol* 1985;60:315-22.
- 39 Macey MG, Newland AC. CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. *Brit J Haematol* 1990;76:513-20.
- 40 Leung DYM, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. *J Clin Invest* 1987;79:468-72.
- 41 Schifferli JA, Didierjean L, Saurat JH. Immunomodulatory effects of intravenous immunoglobulin G. *J Rheumatol* 1991;18:937-9.
- 42 Arend WP, Smith MF, Janson RW, Joslin FG. IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. *J Immunol* 1991;147:1530-5.
- 43 Shimozato T, Iwata M, Kawada H, Tamura N. Human immunoglobulin preparation for intravenous use induces elevation of cellular cyclic adenosine 3':5'-monophosphate levels, resulting in suppression of tumour necrosis factor alpha and interleukin-1 production. *Immunology* 1991;72:497-501.
- 44 Van Schaik IN, Lundkvist I, Vermeulen M, Brand A. Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. *J Clin Immunol* 1992;12:1-10.
- 45 Bartlett WC, Purchio A, Fell HP, Noelle RJ. Cognate interactions between helper T cells and B cells. VI. TGF- β inhibits B cell activation and antigen-specific, physical interactions between T_H and B cells. *Lymphokine Cytokine Res* 1991;10:177-83.
- 46 Kehrl JH, Taylor A, Kim S-J, Fauci AS. Transforming growth factor- β is a potent negative regulator of human lymphocytes. *Ann NY Acad Sci* 1991;628:165-8.
- 47 Ravetch JV, Kinet J-P. Fc receptors. *Annu Rev Immunol* 1991;9:457-92.
- 48 Overweg J, Engelfriet CP. Cytotoxic leucocyte isoantibodies formed during the first pregnancy. *Vox Sang* 1969;16:97-104.
- 49 Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). *Clin Exp Immunol* 1993;92:369-72.